Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Cipla
Novartis
Healthtrust
US Department of Justice
Accenture
UBS
Fish and Richardson
Federal Trade Commission
Deloitte

Generated: February 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,713,446

« Back to Dashboard

Which drugs does patent 6,713,446 protect, and when does it expire?

Patent 6,713,446 protects VELCADE and is included in one NDA.

Protection for VELCADE has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has nineteen patent family members in twelve countries.
Summary for Patent: 6,713,446
Title: Formulation of boronic acid compounds
Abstract:The present invention provides stable compounds prepared from boronic acid and lyophilized compounds thereof of the formula (1): ##STR1## in which Z.sup.1 and Z.sup.2 are moieties derived from sugar. The invention also provides methods for preparing such compounds. Lyophilizing a mixture comprising a boronic acid compound and a moiety derived from sugar produces a stable composition that readily releases the boronic acid compound upon reconstitution in aqueous media.
Inventor(s): Gupta; Shanker Lal (Rockville, MD)
Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services (Washington, DC)
Application Number:10/056,567
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;

Drugs Protected by US Patent 6,713,446

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Millennium Pharms VELCADE bortezomib INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 021602-001 May 13, 2003 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,713,446

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,699,835 Formulation of boronic acid compounds ➤ Try a Free Trial
6,958,319 Formulation of boronic acid compounds ➤ Try a Free Trial
7,109,323 Formulation of boronic acid compounds ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,713,446

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2002243646 ➤ Try a Free Trial
Cyprus 1117484 ➤ Try a Free Trial
Canada 2435124 ➤ Try a Free Trial
Canada 2435146 ➤ Try a Free Trial
Germany 60239384 ➤ Try a Free Trial
Denmark 1355910 ➤ Try a Free Trial
European Patent Office 2251344 ➤ Try a Free Trial
Denmark 2251344 ➤ Try a Free Trial
European Patent Office 1355910 ➤ Try a Free Trial
European Patent Office 1360189 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Teva
Express Scripts
Harvard Business School
Cerilliant
Baxter
Citi
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot